Adamas Announces New Employment Inducement Grant
January 10, 2020 16:30 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted two new...
Adamas Provides Preliminary Fourth Quarter and Full Year 2019 GOCOVRI® Product Sales and Outlines Key Priorities for 2020
January 08, 2020 09:15 ET
|
Adamas Pharmaceuticals, Inc.
-- Product sales expected to be approximately $16.3 million for fourth quarter 2019 and approximately $54.6 million for full year 2019 -- -- Total prescriptions of approximately 7,160 for fourth...
Adamas Announces Settlement of Patent Litigation with Sandoz Inc.
January 02, 2020 09:00 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful...
Adamas Announces Top-Line Results from INROADS Phase 3 Trial of ADS-5102 for Multiple Sclerosis Patients with Walking Impairment
December 17, 2019 09:00 ET
|
Adamas Pharmaceuticals, Inc.
- INROADS study achieved its primary endpoint (proportion of responders with at least a 20% improvement from baseline to Week 12) - - Dose-response observed for both efficacy and safety - - Safety...
Adamas Announces New Employment Inducement Grant
December 09, 2019 16:50 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted four new...
Adamas to Present at Upcoming Evercore ISI and Piper Jaffray Investor Conferences
November 21, 2019 16:02 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous...
Adamas Announces New Employment Inducement Grant
November 08, 2019 16:01 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted three...
Adamas Reports Third Quarter 2019 Financial Results
November 07, 2019 16:03 ET
|
Adamas Pharmaceuticals, Inc.
- Third quarter GOCOVRI® product sales of $13.9 million; total prescriptions grew to approximately 6,640 - Topline results from INROADS Phase 3 study of ADS-5102 (GOCOVRI) for walking impairment in...
Adamas to Announce Third Quarter 2019 Financial Results and Host Conference Call on November 7, 2019
October 30, 2019 16:30 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2019 third quarter financial results on Thursday,...
Adamas Announces New Employment Inducement Grant
October 08, 2019 16:03 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Oct. 08, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted five new...